Biopharmaceutical manufacturer BioMarin is giving 340B covered entities refunds for overcharges on five of its six approved medicines from Q1 2019 through Q4 2020.

BioMarin Paying Refunds for Two Years of 340B Overcharges on Pricey Drugs

Biopharmaceutical manufacturer BioMarin is giving 340B covered entities refunds for overcharges on five of its six approved medicines from Q1 2019 through Q4 2020.

 

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content